1.    Research Framework

1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

2.    Research Methodology

2.1. Qualitative Research

2.1.1.   Primary & Secondary Sources

2.2. Quantitative Research

2.2.1.   Primary & Secondary Sources

2.3. Breakdown of Primary Research Respondents, By Region

2.3.1.   Secondary Research

2.3.2.   Primary Research

2.4. Breakdown of Primary Research Respondents

2.5. Market Size Estimation

2.6. Assumption for The Study

2.7. Market Breakdown & Data Triangulation

3.    Executive Summary

4.    Global Malignant Pleural Mesothelioma Insights

4.1. DROC Analysis

4.1.1.   Growth Drivers

4.1.2.   Restraints

4.1.3.   Opportunities

4.1.4.   Challenges

4.2. Technological Landscape

4.3. Regulatory Framework

4.4. Company Market Share Analysis, 2019

4.5. Porter’s Five forces analysis

4.5.1.   Bargaining Power of Suppliers

4.5.2.   Bargaining Power of Buyers

4.5.3.   Threat of New Entrants

4.5.4.   Threat of Substitutes

4.5.5.   Intensity of Rivalry

5.    Global Malignant Pleural Mesothelioma Market Overview

5.1. Market Size & Forecast by Value, 2016-2026

5.1.1.   By Value (USD Million)

5.2. Market Share & Forecast 2016-2026

5.2.1.   By Route of Administration

5.2.1.1.       Oral

5.2.1.2.       Parenteral

5.2.2.   By Drug Class

5.2.2.1.       Pemetrexed and Combination

5.2.2.2.       Cisplatin and Combination

5.2.2.3.       Carboplatin and Combination

5.2.2.4.       Gemcitabine and Combination

5.2.2.5.       Vinorelbine and Combination

5.2.2.6.       Other Combination

5.2.3.   By Distribution Channel

5.2.3.1.       Hospital Pharmacies

5.2.3.2.       Retail Pharmacies

5.2.3.3.       Oncology Centers

5.2.4.   By Region

5.2.4.1.       North America

5.2.4.2.       Europe

5.2.4.3.       Asia Pacific

5.2.4.4.       Latin America

5.2.4.5.       Middle East & Africa

6.    North America Malignant Pleural Mesothelioma Market

6.1. Market Size & Forecast by Value, 2016-2026

6.1.1.   By Value (USD Million)

6.2. Market Share & Forecast 2016-2026

6.2.1.   By Route of Administration

6.2.2.   By Drug Class

6.2.3.   By Distribution Channel

6.2.4.   By Country

6.2.4.1.       U.S

6.2.4.2.       Canada

7.    Europe Malignant Pleural Mesothelioma Market

7.1. Market Size & Forecast by Value, 2016-2026

7.1.1.   By Value (USD Million)

7.2. Market Share & Forecast 2016-2026

7.2.1.   By Route of Administration

7.2.2.   By Drug Class

7.2.3.   By Distribution Channel

7.2.4.   By Country

7.2.4.1.       Germany

7.2.4.2.       U.K

7.2.4.3.       France

7.2.4.4.       Italy

7.2.4.5.       Spain

7.2.4.6.       Rest of Europe

8.    Asia Pacific Malignant Pleural Mesothelioma Market

8.1. Market Size & Forecast by Value, 2016-2026

8.1.1.   By Value (USD Million)

8.2. Market Share & Forecast 2016-2026

8.2.1.   By Route of Administration

8.2.2.   By Drug Class

8.2.3.   By Distribution Channel

8.2.4.   By Country

8.2.4.1.       China

8.2.4.2.       India

8.2.4.3.       Japan

8.2.4.4.       South Korea

8.2.4.5.       Rest of Asia Pacific

9.    Latin America Malignant Pleural Mesothelioma Market

9.1. Market Size & Forecast by Value, 2016-2026

9.1.1.   By Value (USD Million)

9.2. Market Share & Forecast 2016-2026

9.2.1.   By Route of Administration

9.2.2.   By Drug Class

9.2.3.   By Distribution Channel

9.2.4.   By Country

9.2.4.1.       Brazil

9.2.4.2.       Mexico

9.2.4.3.       Argentina

9.2.4.4.       Rest of Latin America

10. Middle East & Africa Malignant Pleural Mesothelioma Market

10.1.             Market Size & Forecast by Value, 2016-2026

10.1.1.                By Value (USD Million)

10.2.             Market Share & Forecast 2016-2026

10.2.1.                By Route of Administration

10.2.2.                By Drug Class

10.2.3.                By Distribution Channel

10.2.4.                By Country

10.2.4.1.    Saudi Arabia

10.2.4.2.    UAE

10.2.4.3.    South Africa

10.2.4.4.    Rest of Middle East & Africa

11.Company Profile (Company Overview, Financial Matrix, Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

11.1.             AstraZeneca Plc.

11.2.             Bristol-Myers Squibb Company

11.3.             F. Hoffmann-La Roche Ltd.

11.4.             Merck & Co., Inc.

11.5.             Novartis AG

11.6.             Pfizer Inc.

11.7.             Sanofi

11.8.             Eli Lilly and Company

11.9.             Teva Pharmaceuticals

11.10.          Boehringer Ingelheim GmbH

11.11.          Mylan NV.

11.12.          Fresenius Kabi AG

11.13.          Sun Pharmaceuticals Industries Ltd

11.14.          Corden Pharma International GmbH

11.15.          Concordia International Corp

11.16.          Other Prominent Players

List of Figures:

Fig: Global Malignant Pleural Mesothelioma Segmentation

Fig: Company Market Share Analysis, 2019

Fig: Global Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026

Fig: Global Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026

Fig: Global Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026

Fig: Global Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Global Malignant Pleural Mesothelioma Market Share, By Region, By Value, 2016-2026

Fig: North America Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026

Fig: North America Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026

Fig: North America Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026

Fig: North America Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026

Fig: North America Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026

Fig: North America Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026

Fig: Europe Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026

Fig: Europe Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026

Fig: Europe Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026

Fig: Europe Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026

Fig: Europe Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Europe Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026

Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026

Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026

Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026

Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026

Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Asia-Pacific Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026

Fig: Latin America Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026

Fig: Latin America Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026

Fig: Latin America Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026

Fig: Latin America Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026

Fig: Latin America Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Latin America Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026

Fig: Middle-East & Africa Malignant Pleural Mesothelioma Market Size, By Value (USD Million), 2016-2026

Fig: Middle-East & Africa Malignant Pleural Mesothelioma Market Y-o-Y Growth, By Value, 2017-2026

Fig: Middle East & Africa Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2016-2026

Fig: Middle East & Africa Malignant Pleural Mesothelioma Market Share, By Drug Class, By Value, 2016-2026

Fig: Middle East & Africa Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2016-2026

Fig: Middle East & Africa Malignant Pleural Mesothelioma Market Share, By Country, By Value, 2016-2026

List of Tables:

Table: Global Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026

Table: Global Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026

Table: Global Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026

Table: Global Malignant Pleural Mesothelioma Market Size, By Region, By Value, 2016-2026

Table: North America Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026

Table: North America Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026

Table: North America Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026

Table: North America Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026

Table: Europe Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026

Table: Europe Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026

Table: Europe Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026

Table: Europe Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026

Table: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026

Table: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026

Table: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026

Table: Asia-Pacific Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026

Table: Latin America Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026

Table: Latin America Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026

Table: Latin America Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026

Table: Latin America Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026

Table: Middle East & Africa Malignant Pleural Mesothelioma Market Size, By Route of Administration, By Value, 2016-2026

Table: Middle East & Africa Malignant Pleural Mesothelioma Market Size, By Drug Class, By Value, 2016-2026

Table: Middle East & Africa Malignant Pleural Mesothelioma Market Size, By Distribution Channel, By Value, 2016-2026

Table: Middle East & Africa Malignant Pleural Mesothelioma Market Size, By Country, By Value, 2016-2026

Table: AstraZeneca Plc. Financial Analysis

Table: Bristol-Myers Squibb Company Financial Analysis

Table: F. Hoffmann-La Roche Ltd. Financial Analysis

Table: Merck & Co., Inc. Financial Analysis

Table: Novartis AG Financial Analysis

Table: Pfizer Inc. Financial Analysis

Table: Sanofi Financial Analysis

Table: Eli Lilly and Company Financial Analysis

Table: Teva Pharmaceuticals Financial Analysis

Table: Boehringer Ingelheim GmbH Financial Analysis

Table: Mylan NV. Financial Analysis

*Financial Information of non-listed companies will be provided as per the availability

**The segmentation and the companies are subjected to modification based on the in-depth secondary for the final deliverable.